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Blood transfusion is made possible because, in most countries and organizations, altrui­
stic individuals voluntarily, anonymously, and generously donate (without compensation) 
either whole blood or separated components that are then processed and distributed 
by professionals, prior to being allocated to recipients in need. Being part of modern 
medicine, blood transfusion uses so­called standard blood components when relative 
to cellular fractions and fresh plasma. However, as will be discussed in this paper, 
strictly speaking, such so­called labile blood components are not completely standard. 
Furthermore, the prevalent system based on voluntary, non­remunerated blood donation 
is not yet universal and, despite claims by the World Health Organization that 100% of 
blood collection will be derived from altruistic donations by 2020 (postponed to 2025), 
many obstacles may hinder this ambition, especially when relative to the collection of the 
enormous amount of plasma destined for fractionation into plasma derivative or drugs. 
Finally, country organizations also vary due to the economy, sociology, politics, and epi­
demiology. This paper then, discusses the particulars (of which ethical considerations) 
of blood transfusion diversity and the consequences for donors, patients, and society.
Keywords: transfusion, blood donation, blood processing, blood components, ethics
inTRODUCTiOn
Blood and blood components (BCs) for transfusion chiefly originate from donations made by altru-
istic individuals. However, although 100% voluntary non-remunerated blood donation (VNRD) is 
the goal that has been set (by 2020 as publicized by the World Health Organization WHO—later 
revised to 2025 in some areas) (1, 2), it is far from being achieved at the present time for various 
reasons linked to contingency (3), and the emergence in low/middle-income countries of modern 
health-care services requiring more transfusion prescriptions. Blood for therapeutic use comes into 
two sets: (1) the one consists in labile blood components (LBCs) comprising essentially the cellular 
components [red blood cells concentrates (RBCCs) and platelet concentrates, PCs as well as part of 
therapeutic plasma, principally fresh frozen plasma FFP]; and (2) the other one consists in plasma 
derived or fractionated drugs, and occasionally in FFP obtained from large pools and subjected to 
stringent pathogen reduction. While the former is principally handled by blood establishments (BEs), 
many of them overruled by the public sector or Non Governmental, non-for-profit, organizations 
such as the Red-Cross/Red-Crescent, the latter is largely handled by the plasma fraction industry 
within the private, for-profit sector.
Labile blood components are usually labeled as “standard blood products,” and thus refer to 
guidelines such as the Council of Europe’s “Guide to the preparation, use and quality assurance 
of blood components” (4). However, all LBCs referring to the same label are, in fact, significantly 
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different from each other: they depend on the donor, the process 
and the storage characteristics which are not consistent, as each 
consists either in single donor originating units or small pools 
(5 in mean, and >12 by all means); minipools apply to PCs and 
therapeutic plasma. Indeed, as each LBC reflects both the genetic 
and non-genetic-based characteristics of the donors (referred to 
as “storage lesions”), they all differ from one another despite con-
siderable efforts made to minimize deviations in their process.
This paper will briefly outline the most visible community 
forms of and differences in LBCs, and the way in which differ-
ences can affect outcomes in: (1) recipients; (2) health policies and 
economics (as essential additional safety procedures can result in 
even more complex disparities between LBC inventories). The 
circumstances of blood collection and how ethics are concerned 
when blood supply does not meet demand or when marketing 
creates new markets will also be discussed.
AS THe eSSenTiAL DeTeRMinAnT in 
TRAnSFUSiOn, BLOOD RePReSenTS  
A COMMOn MATTeR FOR HUMAnS
Every human depends on nearly normal blood functions to 
survive. Moderate alterations may result in sub-physiological 
functioning, while more severe defects can be corrected by either 
drugs or blood derivatives (when available), or both, pending 
anticipated gene correction. Blood characterizes species and can-
not be safely exchanged between species, even close ones such as 
humans and apes. Human blood transfusion can nevertheless be 
processed within the human species provided major compatibility 
rules are respected. This property first allowed blood transfusion 
to be performed in emergency situations, and later, with techno-
logical advances, to be applied almost routinely, despite the fact 
that “routine” is a word that never applies to blood transfusion 
from either the donor’s or the recipient’s perspective (5, 6).
Donated blood is humanity (7, 8) and ideally, VNRD blood 
is “pure” humanity, yet replacement donation shares the values 
of assistance and cannot be considered non-altruistic, even if a 
certain degree of social pressure cannot be ruled out (3). Maybe 
the lowest common denominator is the root symbol of blood, 
its sacred characteristic, whatever sacred may mean to people, 
ranging from religious to atheistic sentiments (9). Thanks to 
initiatives like Blood Donor Day on the 14th of June, it can be 
acknowledged on the highest scale that many people worldwide 
share the idealistic human view of blood donation for transfusion 
purposes (10). Ideally, this standpoint should make sure that such 
a process expands and infuses in areas where VNRD is not yet 
achievable. However, the situation is far from universal or exem-
plary. Three taints can be outlined as follows: (1) as the demand 
for BCs expands in many countries, BEs start applying marketing 
methods to attain prospective new blood donors, potentially 
altering the voluntary aspect of donation, or the benevolence (or 
the absence of profit) (11). The same holds true for plasma collec-
tors within the industry (12–16). (2) The benefits of blood have 
been distorted to serve non-life-threatening medical conditions, 
and BCs have entered the for-profit market and business where 
blood is being increasingly used in welfare clinics for doping or 
cosmetic applications (17, 18). This merchandized blood may, 
therefore, no longer be available for therapeutic and medical 
indications, potentially worsening the shortage problem and 
ultimately leading BEs to use enhanced marketing tools and enter 
a vicious circle. (3) Blood and BCs for research now represent an 
expanding market, they can either be “conventional” as BEs trade 
left-overs from test tubes or residues from blood processing, or 
BCs purposefully processed, i.e., BEs collect blood from VNRDs 
not eligible for the therapeutic pathway or presenting character-
istics required for specific research. In those cases, VNRDs are 
usually informed that all or part of their donation will be used for 
research programmes and they may object to this use. Moreover, 
some donors sell blood for specific research programmes, with 
the blood generally being collected outside of BEs; this is possible 
in some countries but is strictly forbidden in others. Research 
ethics committees would prevent these possibilities.
SiMiLARiTieS OF HUMAn BLOOD
As has already been outlined, one common platform for humans 
considering blood is the general anthropological consideration of 
this “fluid” which is both material (the blood tissue) and spiritual 
or the like (altruism, attraction/repulsion, life and death, genet-
ics and lineages, war and peace, and so forth) (9). Regarding its 
materiality, human blood is unique to the species, and there is 
by no means any significant difference between ethnic groups, 
which refutes previous racist theories on the purity of blood. 
There are indeed certain variations that vary in their frequency in 
ethnic groups as will be presented in the next section of this paper, 
but none of them prevent donated blood from being issued to 
any other human, apart from major (ABH) blood (in fact, tissue) 
antigen group compatibility. These fundamental characteristics 
allow the principle of blood transfusion and, moreover, of uni-
versal blood transfusion, once the major restriction of the ABH 
system is taken care of.
DiveRSiTieS in HUMAn BLOOD AnD BCs 
FOR TRAnSFUSiOn
In contrast to what has been presented above, no siblings have 
identical blood. Indeed, even monozygotic twins display genetic 
and epigenetic differences. Whereas the Mendelian distribution 
of HLA antigens is transmitted in blocks (haplotypes), HLA 
diversity between humans ranges from between 106 and 107 (19). 
HLA polymorphism limits, to some extent, platelet and leukocyte 
availability and may also create complications such as immuniza-
tion (20). Platelet antigens add diversity by bringing more than 
30 additional groups often with two alleles each (about 5 matter 
essentially in transfusion) (21, 22). The diversity of erythrocyte 
antigenic alleles is not only huge (by the thousands) but is also 
non-haplotypic, offering a tremendous assortment of individual 
cell markers which is fascinating if we consider the uniqueness 
of each human, but limits the possibility of matching blood 
groups for transfusion (23). In fact, half a dozen such antigens are 
considered routine, allowing for wide-scale transfusion. It should 
be noted that not all individuals are equal and some individuals 
TABLe 1 | Parameters having proven or theoretical influence on the quality of the 
processed blood component (BC).
Main 
categories
Main items adding diversity Level of diversity
Donor 
dependent 
parameters 
(genetically 
controlled)
•	Sex/gender
•	 Immunogenetic characteristics (blood 
groups)
•	Natural iso­antibodies
•	…
•	Two
•	By the thousands 
(millions if applied 
also to HLA 
antigens)
•	Variable
Donor 
dependent 
parameters 
(only partly 
genetically 
controlled)
•	 Immunization status
•	Nutrition, metabolism
•	Hygiene and intoxications (therapeutic 
and recreational drugs, supplements, 
alcohol, tobacco)
•	Meal; or fast
•	Nycthemeral cycle
•	Genital cycle and periods
•	Outside temperature condition
•	…
Hundreds of 
influential parameters
Donor 
independent 
parameters 
(BC 
processing)
•	Shipping time and temperature
•	Needles, plastics and bags, 
rotators, automats for collection and 
intermediate storage
•	Devices for cell separation
•	Working temperature
•	Additives (anticoagulant, solutions, 
pathogen inactivation, etc.)
•	Filtration steps (meshes, temperature, 
timing, etc.)
•	Pooling steps
•	Preservation conditions
•	Physical interactions in shelf­life 
conditions (stacking, shocks, thermic 
differences, shipping, etc.)
•	Variable
•	Dozens influential 
parameters
Patient 
(recipient, 
beneficiary) 
dependent 
parameters
•	Blood group
•	 Immunization status
•	Matching conditions
•	By the thousands
Each parameter being independent from the preceding one, diversity is created by the 
multiplication as opposed to the addition of all. The final diversity goes by the million or 
more. Not all parameters are equally influential but it clearly appears from the table that 
one given BC collected by one individual, despite being “standardized” to a norm,  
is unlikely to be “standard.”
3
Garraud and Tissot Blood and Components
Frontiers in Medicine | www.frontiersin.org April 2018 | Volume 5 | Article 84
can be easily transfused (the vast majority) while others with rare 
blood groups cannot, requiring special programs with technical, 
ethical, and organizational problems. Similarly, there is diversity 
in people’s propensity to become alloimmunized after blood trans-
fusion, because HLA loci make people good or bad responders to 
RBC, platelet, or leukocyte antigens (a common law in innate and 
adaptive immune responses that varies in individuals) (24–26).
With respect to LBCs, despite being called “standard,” and 
their largely similar appearance category by category, they are 
not, in fact, all the same. They are defined as standard because 
they fall within a range of maximum and minimum levels of 
either desired and undesired constituents, and only a few param-
eters are evaluated among the thousands of variables that make 
individuals’ blood differ from another (4). Furthermore, for each 
category of LBC, besides the genetic variations between donors 
that transfer characteristics to the donated component (gender, 
tissue and HLA genotype, erythrocyte antigen genotype, platelet 
antigen genotype, protein variants, etc.), there are additional vari-
ation parameters that depend on the donors: the time of donation 
(morning, afternoon, after a meal or fasting, drug and dietary 
supplement intake, menstrual cycle for non-menopaused women, 
diet, hygiene habits, and many other parameters) (27–29). All of 
these parameters may influence the final characteristics of the 
LBC, though there is no evidence as yet of the effect apart from 
the presence of soluble antibodies against blood cell antigens 
(iso-anti-A or B; anti-HLA in females who have been pregnant). 
BEs extend the variety since the addition and diversification of 
devices, machines and automats multiply heterogeneity (Table 1 
aims to illustrate this). Finally, shelf-life duration multiplies LBC 
delivery diversity by 41 for RBCCs (in theory: 42 minus 1 day, as 
1 day is needed to obtain all the parameters allowing the labeling 
and issue of the RBCC) (30) and 4 (5 minus 1 day) for PCs. 
It has further been noticed near two decades ago that RBCs do not 
recirculate the same depending on storage conditions of the com-
ponent (one ¼ of the infused RBCs even never recirculate) (31).
What then is the clinical relevance of such diversity? The 
case of storage lesions has been extensively studied (32–34), 
having basically identified two sets of lesions: reversible and 
irreversible lesions (35). Conflicting data have been obtained 
from both experimental and clinical data, sparking disputes over 
the rationale for using fresh as opposed to old blood (36–38). 
In simple terms, it appears that neither fresh nor old blood is 
clearly defined, nor is the readout (patient outcome) providing 
conclusive information, and relevant clinical trials are still needed 
to resolve this issue (39–41). This issue is of utmost importance 
as it may revoke the current blood-banking paradigm (meaning 
that conflicts of interest when blood banks happen to be research 
principal investigators are non-negligible).
DiSPARiTieS in PUBLiC HeALTH 
POLiCieS
Labile blood components are not considered univocal in various 
countries and systems, though they are not considered to be drugs 
according to Directive 2002/98/EC (42), in contrast to plasma frac-
tions or derivatives [Directive 2001/83/EC (43)], or industrially 
prepared and solvent-detergent secured therapeutic plasma origi-
nating from large pools. Some national regulations do, however, 
consider labile LBCs to be drugs, as is the case in Switzerland; and 
WHO recently (2015) added blood and blood derivatives to its 
list of essential medicines (44). Semantics between medicines and 
drugs are imprecise, however, and this decision has displeased 
a number of blood donor associations who are batting against 
confusion with LBCs and plasma derivatives (45). Furthermore, 
the logistics by which certified LBCs can be delivered to patients 
varies considerably between countries: according to the European 
directive, there are basically two main actors: BEs which collect, 
process, test, and distribute BCs, and Hospital Blood Banks or 
HBBs which acquire LBCs from BEs, build up an inventory and 
deliver selected LBCs to patients upon ad hoc immunohaemato-
logical matching (4). On some occasions, BE and HBB functions 
can be held by the same entity (as, e.g., in France).
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In addition, Council of Europe directorate EDQM requests 
that BEs apply a minimum platform for blood testing, with addi-
tional options for BEs willing to raise the LBC safety level with, 
for example, the implementation of nucleic acid testing (NAT) 
(4). Some BEs perform NAT on each donation, even on frequent 
donors’ donations, while others restrict it to new donations. NAT 
is applied to both pools and individuals, and some BEs that used 
NAT have reverted back to non-NAT because of its relatively low 
(and debatable) cost-effectiveness (46).
In short, there is significant heterogeneity in stances on 
the availability of LBCs to patients through organizations and 
countries’ public health policies. Consistent efforts have been 
made by large bodies such as EDQM, the American Blood Bank 
Association or the International Society for Blood Transfusion 
ISBT to define safety and quality parameters that should apply to 
each issued LBC; however, this is still a range above and beyond 
which the LBC should not conform to standards; if testing is indi-
vidual for most infectious markers (and even some are tested in 
pools), hematological markers are frequently tested by sampling 
to define quality (4). This is the reason why we call attention here 
on the false homogeneity of LBCs despite they go by the noun of 
“standard.” This is in sharp contrast to the actual standardization 
of plasma derivatives obtained from 100 of 1000s of collections 
and subjected to an industrial processing (47).
DiSPARiTieS wiTHin eTHiCAL 
COnSiDeRATiOnS
Ethics are largely cultural and it is difficult to establish a plat-
form that fits all situations worldwide. Nevertheless, as early as 
1975, WHO declared that sustainable efforts should be made by 
all countries to collect blood from VNRDs. WHO later set the 
objective of 100% VNRD by 2020 (the Melbourne Declaration, 
2009) (1). The EDQM has also declared itself in favor of a general-
ized objective of 100% VNRD where possible (4). The Oviedo 
Convention (1997), set up under the auspices of the Council of 
Europe, has established standards for ethics in the field of human 
rights and dignity, with regard to the use of tissues of human 
origin (including blood) (48). Nonetheless, many states have been 
late in signing this convention and others have not yet ratified 
it. WHO, considering that many countries could not achieve the 
2020 VNRD objective, postponed it to 2025 for certain Middle-
Eastern countries. State WHO and ISBT in its revised code of 
Ethics, paid and compensated donations should no longer be 
acceptable; replacement donations remain questionable (49). The 
issue of paid versus unpaid plasma collection has been challenged 
by advocates for the plasma fractionation industry (13, 14, 16) 
(the case of paid cell donations is still existing in certain countries 
including Europe but apparently on the decline worldwide). It is 
worth noting that a very interesting study was published in 2012 
questioning the ban on financial contracts with blood donors 
in Africa, with the declared objective to reduce the infectious 
burden on “donated” blood (50). This last example questions the 
universality of ethical values of blood donation when coming to 
strengthening safety in LBC beneficiaries, opening an additional 
ethical dilemma. Next, when this comes to plasma for fractiona-
tion, there have been requests that collection and fractionation 
are more equally dispatched in countries that prescribe most 
to do justice to patients in need in case there is shortage and to 
alleviate the burden of (paid) collection in countries hosting the 
majority of plasma collectors such as the USA (51).
We offer an opinion here: as opposed to normative ethics (the 
Oviedo Convention, the ISBT Code of Ethics), reflective ethics 
(anthropological and philosophical) are preferred in order to 
move forward with the safe use (for donors, recipients, stakehold-
ers and society members, i.e. people, civilians and tax payers) of 
substances of human origin (41). In the meantime, there is clear 
evidence that ethics are extremely cultural and embedded with 
acknowledged or hidden religious sentiments with the popula-
tions concerned.
In short, it should be noticed that blood within the transfusion 
process offers an additional paradox: while the LBCs are relatively 
inhomogeneous relative to active constituents though relatively 
homogenous relative to the so-called ethicality of their collection, 
this is the other way around for plasma derivatives that are remark-
ably homogenous and standardized relative to active constituents 
but may be obtained both within the profit and the non-for-profit 
sectors. The latter case has been recently (2016) the subject of 
important debated in France and Switzerland and journalists 
reported both in the paper and the TV press on some potential 
malpractice with respect to donors’ own safety and vulnerability.
COnCLUDinG ReMARKS
The transfusion process is at the crossroads of a multitude of para-
doxes (42). It is one of the only medicines that rely on material 
outside the control of the pharmaceutical industry if we exclude 
plasma for fractionation. It professes to be precision medicine, 
yet the issued LBC comprises ±20% (or more) of the expected 
therapeutic constituent. It professes to be personalized medicine, 
but blood groups between donors and recipients match for the 
vast minority. It is prescribed for the most fragile patients, yet 
practitioners prove to have very limited knowledge on it (accord-
ing to recent surveys, they usually know which is the target of a 
biosimilar drug or a therapeutic monoclonal antibody, but only 
largely relative to LBCs) (43). We believe it is important to advo-
cate for prescribing doctors to receive further training on LBCs 
and transfusion medicine–setting apart the case of standardized 
plasma derivative or drugs—education and training are essential 
to understanding and respecting blood donors and donated 
LBCs, to making wise choices, and to the optimal management 
of patients’ blood and donated LBCs, within the limitations of 
prevailing uncertainty (Garraud et  al., in preparation). Being 
knowledgeable in the face of uncertainty would prevent a com-
parison of apples and oranges in published works, even in high-
quality journals. It would be practical for prescribing doctors to 
forward their everyday questions to blood transfusion specialists; 
this would certainly be useful in establishing the most appropriate 
training programmes.
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